UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 24, 2014
Adamas Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36399 |
|
42-1560076 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
of incorporation) |
|
|
|
|
|
1900 Powell Street, Suite 750 |
|
94608 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (510) 450-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 24, 2014, Adamas Pharmaceuticals, Inc. (the “Company”) and Actavis plc. (“Actavis”) announced that the U.S. Food and Drug Administration (the “FDA”) has approved the New Drug Application (the “NDA”) for Namzaric™, formerly known as MDX-8704. As a result, the Company is entitled to a $30 million milestone payment pursuant to the Company’s license agreement with Forest Laboratories Holdings Limited, a subsidiary of Actavis.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Adamas Pharmaceuticals, Inc. | |
|
|
| |
|
|
| |
|
Dated: December 24, 2014 |
| |
|
|
By: |
/s/Gregory Went |
|
|
|
Gregory Went |
|
|
|
Chief Executive Officer |